Synthetic somatostatin analogs (SSAs), which are FDA-approved drugs for neuroendocrine tumor and acromegaly treatment, have demonstrated anti-inflammatory activities. Five somatostatin receptor subtypes (SSTR1-5) have been characterized which mediate the effects of SSAs in target tissues [
1]. Octreotide (OCT) and lanreotide (LAN), bind preferentially to SSTR2 and SSTR5, which are widely expressed in a variety of tissues. …